REFERENCES
1. Jezierska M, Stefanowicz J, Romanowicz G, Kosiak W, Lange M. Langerhans cell histiocytosis in children - a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment. Postepy Dermatol Alergol. fevereiro de 2018;35(1):6–17.
2. Haroche J, Cohen-Aubart F, Rollins BJ, Donadieu J, Charlotte F, Idbaih A, et al. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol. fevereiro de 2017;18(2):e113–25.
3. Egeler RM, Katewa S, Leenen PJM, Beverley P, Collin M, Ginhoux F, et al. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci. Pediatr Blood Cancer. outubro de 2016;63(10):1704–12.
4. Tzotzola V, Petrikkos L, Papadakis V, Mitropoulou G, Kelaidi C, Dimitriadis E, et al. Long-term outcome, clinical course and treatment approaches of paediatric langerhans cell histiocytosis: A greek reference centre report. Acta Paediatr Oslo Nor 1992. junho de 2021;110(6):1944–51.
5. Tuysuz G, Yildiz I, Ozdemir N, Adaletli I, Kurugoglu S, Apak H, et al. Langerhans Cell Histiocytosis: Single Center Experience of 25 Years. Mediterr J Hematol Infect Dis. 2019;11(1):e2019035.
6. Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Aricò M, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 20 de junho de 2013;121(25):5006–14.
7. Bhatia P, Singh M, Sharma M, Sharma A, Kakkar N, Radhika S, et al. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival. Blood Cells Mol Dis. maio de 2020;82:102356.
8. Héritier S, Hélias-Rodzewicz Z, Lapillonne H, Terrones N, Garrigou S, Normand C, et al. Circulating cell-free BRAF(V600E) as a biomarker in children with Langerhans cell histiocytosis. Br J Haematol. agosto de 2017;178(3):457–67.
9. Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 6 de novembro de 2014;124(19):3007–15.
10. Bubolz AM, Weissinger SE, Stenzinger A, Arndt A, Steinestel K, Brüderlein S, et al. Potential clinical implications of BRAF mutations in histiocytic proliferations. Oncotarget. 30 de junho de 2014;5(12):4060–70.
11. Nelson DS, Quispel W, Badalian-Very G, van Halteren AGS, van den Bos C, Bovée JVMG, et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood. 15 de maio de 2014;123(20):3152–5.
12. Jang S, Atkins MB. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther. janeiro de 2014;95(1):24–31.
13. Donadieu J, Larabi IA, Tardieu M, Visser J, Hutter C, Sieni E, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 1o de novembro de 2019;37(31):2857–65.
14. Evseev D, Kalinina I, Raykina E, Osipova D, Abashidze Z, Ignatova A, et al. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA. Int J Hematol. dezembro de 2021;114(6):725–34.
15. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 16 de setembro de 2010;116(11):1919–23.
16. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 27 de junho de 2002;417(6892):949–54.
17. Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 4 de setembro de 2014;124(10):1655–8.
18. Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovée JVMG, Patel B, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. junho de 2015;54(6):361–8.
19. Hutter C, Minkov M. Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies. ImmunoTargets Ther. 2016;5:81–91.
20. Héritier S, Jehanne M, Leverger G, Emile JF, Alvarez JC, Haroche J, et al. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. JAMA Oncol. setembro de 2015;1(6):836–8.
21. Gerbaux M, Diallo S, Dedeken L, Dangoisse C, Bott A, Heritier S, et al. Effective rescue treatment with vemurafenib of an infant with high-risk Langerhans cell histiocytosis. Ann Dermatol Vénéréologie. novembro de 2020;147(11):782–5.
22. Donadieu J, Bernard F, van Noesel M, Barkaoui M, Bardet O, Mura R, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 17 de setembro de 2015;126(12):1415–23.
23. Kudo K, Maeda M, Suzuki N, Kanegane H, Ohga S, Ishii E, et al. Hematopoietic Stem Cell Transplantation in Children with Refractory Langerhans Cell Histiocytosis. Blood. 29 de novembro de 2018;132(Supplement 1):4657–4657.
24. Cohen Aubart F, Emile JF, Carrat F, Charlotte F, Benameur N, Donadieu J, et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood. 14 de setembro de 2017;130(11):1377–80.
25. Tardieu M, Néron A, Duvert-Lehembre S, Amine Larabi I, Barkaoui M, Emile JF, et al. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF(V600E) mutated Langerhans cell histiocytosis. Pediatr Blood Cancer. setembro de 2021;68(9):e29140.